"Chemoradiotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment that combines chemotherapy with radiotherapy.
| Descriptor ID |
D059248
|
| MeSH Number(s) |
E02.186.079 E02.319.164 E02.815.160
|
| Concept/Terms |
Chemoradiotherapy- Chemoradiotherapy
- Chemoradiotherapies
- Radiochemotherapy
- Radiochemotherapies
Concurrent Chemoradiotherapy- Concurrent Chemoradiotherapy
- Chemoradiotherapies, Concurrent
- Chemoradiotherapy, Concurrent
- Concurrent Chemoradiotherapies
- Synchronous Chemoradiotherapy
- Chemoradiotherapies, Synchronous
- Chemoradiotherapy, Synchronous
- Synchronous Chemoradiotherapies
- Concurrent Radiochemotherapy
- Concurrent Radiochemotherapies
- Radiochemotherapies, Concurrent
- Radiochemotherapy, Concurrent
- Concomitant Chemoradiotherapy
- Chemoradiotherapies, Concomitant
- Chemoradiotherapy, Concomitant
- Concomitant Chemoradiotherapies
- Concomitant Radiochemotherapy
- Concomitant Radiochemotherapies
- Radiochemotherapies, Concomitant
- Radiochemotherapy, Concomitant
|
Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy".
Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy".
This graph shows the total number of publications written about "Chemoradiotherapy" by people in this website by year, and whether "Chemoradiotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 2 | 0 | 2 |
| 2011 | 12 | 11 | 23 |
| 2012 | 14 | 24 | 38 |
| 2013 | 21 | 30 | 51 |
| 2014 | 20 | 24 | 44 |
| 2015 | 22 | 31 | 53 |
| 2016 | 37 | 19 | 56 |
| 2017 | 38 | 27 | 65 |
| 2018 | 31 | 31 | 62 |
| 2019 | 27 | 24 | 51 |
| 2020 | 21 | 32 | 53 |
| 2021 | 18 | 28 | 46 |
| 2022 | 1 | 23 | 24 |
| 2023 | 3 | 14 | 17 |
| 2024 | 8 | 11 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemoradiotherapy" by people in Profiles.
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
-
Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO). Lancet Oncol. 2024 Oct; 25(10):e489-e500.
-
The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists' Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey-Based Study. AJR Am J Roentgenol. 2024 Oct; 223(4):e2431595.
-
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 Aug 01; 10(8):1111-1115.
-
Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol. 2024 Oct; 31(10):6918-6930.
-
Current State of Neoadjuvant Therapy for Locally Advanced Rectal Cancer. Cancer J. 2024 Jul-Aug 01; 30(4):227-231.
-
The Prognostic Impact of Minimally Invasive Esophagectomy on Survival After Esophagectomy Following a Delayed Interval After Chemoradiotherapy: A Secondary Analysis of the DICE Study. Ann Surg. 2024 Oct 01; 280(4):650-658.
-
Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2024 Sep-Oct; 14(5):398-425.
-
Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies. Med. 2024 Jun 14; 5(6):487-489.
-
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15; 391(7):585-597.